- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07568626
Factors for Prolonged Hospital Stays in Patients Undergoing ERCP
13 juli 2026 uppdaterad av: Yanglin Pan, Air Force Military Medical University, China
Factors Associated With Prolonged Hospital Stay in Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography: A Prospective, Multicenter Cohort Study
Endoscopic retrograde cholangiopancreatography (ERCP) is a crucial minimally invasive technique for the diagnosis and treatment of biliary and pancreatic diseases.
However, it remains technically demanding and carries a postoperative adverse event (AE) rate exceeding 10% (e.g., pancreatitis, bleeding, and perforation), which subsequently leads to prolonged length of stay (LOS) and increased healthcare costs.
With the rapid acceleration of population aging, the clinical demand for ERCP among the elderly has surged.
Although ERCP is generally considered safe for older adults, advanced age also increases the risk of ERCP-related AEs and prolonged LOS.
While previous studies investigated the outcomes of ERCP in elderly patients, those studies were predominantly retrospective, accompanied by selection bias.
Moreover, insufficient factors were included in those retrospective studies.
Importantly, some aging-related parameters, such as frailty, functional reserve, cognitive and psychological status, were not included in previous studies.
Therefore, the investigators conducted a prospective, multicenter cohort study aimed at investigating outcomes in elderly patients undergoing ERCP and comprehensive factors (patient-related, procedure-related, and geriatric factors) associated with adverse outcomes.
Studieöversikt
Status
Rekrytering
Betingelser
Studietyp
Observationell
Inskrivning (Beräknad)
504
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studiekontakt
- Namn: Yanglin Pan, M.D
- Telefonnummer: 13991811225
- E-post: yanglinpan@hotmail.com
Studieorter
-
-
Fujian
-
Xiamen, Fujian, Kina, 361009
- Rekrytering
- Xiamen Hong'ai Hospital
-
Kontakt:
- Rongchun Zhang, M.D
- Telefonnummer: 15829395908
- E-post: zrc.700502@163.com
-
-
Shaanxi
-
Xi'an, Shaanxi, Kina, 710000
- Rekrytering
- Xijing Hospital of Digestive Diseases
-
Kontakt:
- Yanglin Pan, M.D
- Telefonnummer: 13991811225
- E-post: yanglinpan@hotmail.com
-
Xi'an, Shaanxi, Kina, 710054
- Rekrytering
- Department of Gastroenterology, 986 Hospital of Xijing Hospital, Fourth MilitaryMedical University
-
Kontakt:
- Jun Wang, M.D
- Telefonnummer: 86-29-84734201
- E-post: Wangjundoctor@aliyun.com
-
Xi'an, Shaanxi, Kina, 710038
- Rekrytering
- The Second Affiliated Hospital of Air Force Military Medical University
-
Kontakt:
- Zhenxiong Liu, M.D
- Telefonnummer: 13572276166
- E-post: liuzhx816@126.com
-
Xi'an, Shaanxi, Kina, 710054
- Rekrytering
- Xi'an Honghui Hospital
-
Kontakt:
- Yupeng Shi, M.M
- Telefonnummer: 13891893748
- E-post: xjshiyupeng@163.com
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Äldre vuxen
Tar emot friska volontärer
Nej
Testmetod
Icke-sannolikhetsprov
Studera befolkning
Patients aged ≥ 65 years old who are scheduled to undergo endoscopic retrograde cholangiopancreatography (ERCP) are eligible for our study.
Beskrivning
Inclusion Criteria:
- Patient age ≥ 65 years
- Scheduled to undergo ERCP procedure
Exclusion Criteria:
- Severe cognitive dysfunction
- Severe hearing impairment
- Known or suspected gastrointestinal perforation
- Hemodynamic instability
- Pregnant or lactating women
- Unable to sign the informed consent form
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Prolonged Postoperative Length of Stay
Tidsram: 30 days
|
A binary outcome defined as a postoperative length of stay > 5 days.
It is calculated as the duration from the completion of the ERCP procedure to the date of formal hospital discharge.
|
30 days
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Rate of total adverse events
Tidsram: 30 days
|
Adverse events include ERCP-related or non ERCP-related adverse events
|
30 days
|
|
Total Length of Hospital Stay
Tidsram: 30 days
|
Total length of stay (TLOS), defined as the total duration in days from the date of hospital admission to the date of hospital discharge.
|
30 days
|
|
Post-procedure Length of Hospital Stay
Tidsram: 30 days
|
The number of days from the day of the ERCP procedure to hospital discharge
|
30 days
|
|
Rate of post-ERCP Pancreatitis
Tidsram: 30 days
|
a new or aggravated upper abdominal pain, with an elevated pancreatic enzyme of at least 3 times as the upper limit of normal value 24h after procedure and prolonged hospitalization days for at least 2 days.
This definition was based on a widely recognized Cotton consensus.
|
30 days
|
|
Rate of ERCP-related bleeding
Tidsram: 30 days
|
Bleeding was established according to Cotton criteria.
Mild: a documented decrease in hemoglobin concentration by <3 g/L, without requiring the blood transfusion; Moderate: blood transfusion ≤ 4 units; without need for angiographic or surgery interventions ;Severe: Transfusion: ≥ 5 units or requiring for angiographic or surgery interventions.
|
30 days
|
|
Rate of ERCP-related perforation
Tidsram: 30 days
|
Perforation was established according to Cotton criteria.Mild: slight leakage of fluid or contrast dye, manageable through fluid administration and suction therapy 3 days; Moderate: definite perforation required to be managed for 4-10 days; Severe: management for more than 10 days or requiring for percutaneous or surgical intervention.
|
30 days
|
|
Rate of ERCP-related infection
Tidsram: 30 days
|
Infection was established according to Cotton criteria.Mild: temperature >38℃ for 24-48h; Moderate: Febrile illness requiring >3 days of hospital treatment; endoscopic or percutaneous interventions; Severe: septic shock or requiring surgery.
|
30 days
|
|
Total Hospitalization Costs
Tidsram: 30 days
|
The sum of all medical expenses incurred during the entire hospitalization, denominated in Chinese Yuan (CNY).
This includes costs for medication, laboratory and imaging tests, treatments, procedures, surgical operations, medical supplies, and bed occupancy.
|
30 days
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Faktisk)
15 februari 2026
Primärt slutförande (Beräknad)
1 januari 2027
Avslutad studie (Beräknad)
1 januari 2027
Studieregistreringsdatum
Först inskickad
28 april 2026
Först inskickad som uppfyllde QC-kriterierna
28 april 2026
Första postat (Faktisk)
6 maj 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
14 juli 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
13 juli 2026
Senast verifierad
1 juli 2026
Mer information
Termer relaterade till denna studie
Nyckelord
Andra studie-ID-nummer
- KY20252608-C-1
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
OBESLUTSAM
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .